Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics has announced the appointment of distinguished biopharma executive John Cox, MBA, to its Board of Directors. Mr. Cox has over 25 years of experience in biopharmaceuticals, most notably in his former role as Chief Executive Officer of Bioverativ. In that role, Mr. Cox built, grew and led the company to an $11.6 billion acquisition by Sanofi, which was considered one of the most successful spinouts in biopharma history.

“I am honored to join Sigilon and to contribute to furthering the progress of its novel pipeline of Shielded Living Therapeutics,” said Mr. Cox. “I care deeply about bettering the treatment of chronic diseases and I believe Sigilon’s technology may offer a novel solution for these patients, freeing them from the burden of daily management of their disease.”

Mr. Cox is currently Executive Chairman of Torque Therapeutics. Preceding his work at Bioverativ, Mr. Cox served in several key roles at Biogen, where he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. Mr. Cox holds an MBA from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.

“I’m thrilled to once again work alongside John in pioneering a new first-in-class category of medicine to transform the lives of patients with chronic diseases,” said Rogerio Vivaldi, M.D., MBA, President and Chief Executive Officer of Sigilon. “John’s deep experience in clinical manufacturing and operations will be of immense benefit to Sigilon as we look to enter the clinic next year and as we continue to leverage the Shielded Living Therapeutics™ product platform for the benefit of patients.”

“We’re pleased to welcome John to the Sigilon Board of Directors, where he’ll be an invaluable source of insights around company-building, partnership formation and future pipeline growth,” said Doug Cole, M.D., Chairman of the Board. “I look forward to working alongside him to advance Sigilon’s important mission.”